104 related articles for article (PubMed ID: 3476764)
41. [Antitumor effects of Behenoyl-ara-C (BH-AC) in combination with Idarubicin (IDA) in P 388 leukemic cell bearing mice].
Watanabe A; Kuriyama H; Kiyota T
Gan To Kagaku Ryoho; 1996 Feb; 23(3):291-6. PubMed ID: 8712821
[TBL] [Abstract][Full Text] [Related]
42. [Oral administration of cytarabine ocfosfate and ondansetron hydrochloride in patients with acute myeloid leukemia who can not be treated with intensive chemotherapy:--attempt to make their quality of life better].
Yano K; Matsui H; Fujisawa S
Gan To Kagaku Ryoho; 1998 Feb; 25(3):427-30. PubMed ID: 9492840
[No Abstract] [Full Text] [Related]
43. [Sequential combination of high-dose cytosine arabinoside and L-asparaginase in the treatment of refractory acute leukemia and malignant lymphoma].
Shimazaki C; Fujita N; Nakanishi S; Nishio A; Haruyama H; Nakagawa M; Ijichi H
Gan To Kagaku Ryoho; 1985 Nov; 12(11):2202-7. PubMed ID: 3864396
[TBL] [Abstract][Full Text] [Related]
44. [ACNP therapy for DCMP-resistant acute leukemia (author's transl)].
Naoe T; Hiraiwa A; Akao Y; Tahara T; Yoshikawa H; Yoshikawa S; Naito K; Yamaguchi H
Rinsho Ketsueki; 1981 Oct; 22(10):1538-44. PubMed ID: 6460886
[No Abstract] [Full Text] [Related]
45. ["Small doses" of cytosar in the therapy of acute nonlymphoblastic leukemias].
Kucher RA; Isaev VG; Savchenko VG
Ter Arkh; 1992; 64(7):21-4. PubMed ID: 1440360
[No Abstract] [Full Text] [Related]
46. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
47. Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
HoĊowiecki J; Grosicki S; Kyrcz-Krzemien S; Skotnicki AB; Piatkowska-Jakubas B; Warzocha K; Seferynska I; Zdziarska B
Ann Hematol; 2008 May; 87(5):361-7. PubMed ID: 18074133
[TBL] [Abstract][Full Text] [Related]
48. A comparative trial of remission induction (by cytosine arabinoside, or C.A.R. and thioguanine, or C.A.R. and daunorubicine) and maintenance therapy (by C.A.R. or methylgag) in acute myeloid leukaemia.
Biomedicine; 1973 May; 18(3):192-8. PubMed ID: 4517790
[No Abstract] [Full Text] [Related]
49. [Leukocytosis induced by BH-AC administration--allergic reaction to Casteo oil HCO-60. A case report].
Ohta S; Iwane S; Katsura T; Shimada M; Hayashi S
Rinsho Ketsueki; 1985 Apr; 26(4):555-9. PubMed ID: 3862890
[No Abstract] [Full Text] [Related]
50. [Therapy of patients with myeloid leukemia with small doses of cytosine arabinoside].
Patterson D; Kravtsova VM; Petrova EM; Zabelina TS; Balaian LN
Ter Arkh; 1987; 59(12):81-6. PubMed ID: 3482131
[TBL] [Abstract][Full Text] [Related]
51. Treatment of acute myelogenous leukemia in adults with N4-behenoyl-1-beta-D-arabinofuranosylcytosine.
Kimura K; Ohno R; Amaki I; Hattori K; Hirota Y; Hoshino A; Ichimaru M; Ito M; Kimura I; Maekawa T
Cancer; 1985 Oct; 56(8):1913-7. PubMed ID: 3861233
[TBL] [Abstract][Full Text] [Related]
52. Impact of in vivo administration of interleukin 3 on proliferation, differentiation, and chemosensitivity of acute myeloid leukemia.
Gore SD; Weng LJ; Jones RJ; Cowan K; Zilcha M; Piantadosi S; Burke PJ
Clin Cancer Res; 1995 Mar; 1(3):295-303. PubMed ID: 9815985
[TBL] [Abstract][Full Text] [Related]
53. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
Early AP; Preisler HD; Slocum H; Rustum YM
Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
[TBL] [Abstract][Full Text] [Related]
54. Sequential standard dose mitoxantrone and cytosine arabinoside for newly diagnosed adult acute myeloblastic leukemia.
Al Bahar S; Pandita R; Bavishi K; Savani B
Neoplasma; 1999; 46(1):61-5. PubMed ID: 10355536
[TBL] [Abstract][Full Text] [Related]
55. Clinical pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D-arabinofuranosylcytosine.
Ueda T; Kamiya K; Urasaki Y; Wataya S; Kawai Y; Tsutani H; Sugiyama M; Nakamura T
Cancer Res; 1994 Jan; 54(1):109-13. PubMed ID: 8261429
[TBL] [Abstract][Full Text] [Related]
56. [A phase II study with high-dose cytarabine (NS-075) in adult patients with relapsed and refractory acute leukemia].
Miyawaki S; Mizoguchi H; Tomonaga M; Kanamaru A; Tsukagoshi S; Nakamura T; Ohashi Y; Yoshida S; Ohno R
Gan To Kagaku Ryoho; 1998 Dec; 25(14):2229-42. PubMed ID: 9881080
[TBL] [Abstract][Full Text] [Related]
57. [Should acute myeloblastic leukemias be treated in elderly patients?].
Boivin P; Kahn A; Hakim J; Amar M
Nouv Presse Med; 1972 Apr; 1(17):1161. PubMed ID: 4504162
[No Abstract] [Full Text] [Related]
58. [Adriamycin-aclacinomycin therapy (AA therapy) for acute leukemia unresponsive to BH-AC-DMP therapy].
Kobayashi M; Tahara T
Gan To Kagaku Ryoho; 1983 Jun; 10(6):1473-9. PubMed ID: 6575727
[TBL] [Abstract][Full Text] [Related]
59. [Treatment of acute myeloblastic leukemia by the combination of daunorubicin (or rubidazone) and cytosine arabinoside (apropos of 76 cases)].
Bauters F; Jouet JP; Huart JJ; Jude B; Toussaint B; Goudemand M
Lille Med; 1980 Dec; 25(10):559-68. PubMed ID: 6936592
[No Abstract] [Full Text] [Related]
60. Pharmacologic and clinical studies of N4-behenoyl-1-beta-D-arabinofuranosylcytosine.
Yamada K; Kawashima K; Kato Y; Morishima Y; Tanimoto M; Ohno R
Recent Results Cancer Res; 1980; 70():219-29. PubMed ID: 6766563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
